Phesgo 600mg/600mg Solution for Injection
Marketer
Roche Products India Pvt Ltd
Salt Composition
Pertuzumab (600mg) + Trastuzumab (600mg)
Overview Phesgo 600mg/600mg Solution for Injection
Trastuzumab deruxtecan 600mg/600mg injectable solution combats breast cancer by targeting and eliminating cancerous cells, halting their proliferation. Administered intravenously under medical guidance, dosage and frequency are individualized by your physician based on your condition and may adjust over time. Strict adherence to the prescribed regimen is crucial; deviations can lead to severe adverse reactions. While therapeutic effects might not be immediately apparent, discontinuation should only occur under your doctor's instruction. Common side effects include alopecia, diarrhea, nausea, weariness, and joint pain. This medication can lower blood cell counts (especially white blood cells), increasing infection risk. Regular blood work monitoring, including heart, liver, and kidney function, is essential. Inform your healthcare provider about all other medications you are taking, as interactions may occur. Pregnancy and breastfeeding are contraindicated. Reliable contraception is vital for both partners throughout treatment. A patient support/assistance program exists in India, facilitated by Tata 1mg; inquire with your doctor or call (1800-102-1618) for details.
Primary Ingredients of Phesgo 600mg/600mg Solution for Injection
The provided text is "undefined," which lacks meaning and cannot be rephrased.
Uses of Phesgo 600mg/600mg Solution for Injection
Malignant breast tumor
Major Benefits of Phesgo 600mg/600mg Solution for Injection:
Your healthcare provider will instruct you on the proper administration of this medication.
Common Side effects of Phesgo 600mg/600mg Solution for Injection:
- Hair loss
- Nausea
- Diarrhea
- Joint pain
- Fatigue
How to use Phesgo 600mg/600mg Solution for Injection:
Your healthcare provider will instruct you on the proper administration of this medication.
How Phesgo 600mg/600mg Solution for Injection works:
Phesgo, a 600mg/600mg injectable solution, combines two anti-cancer agents. One, pertuzumab, targets the HER2 protein, a growth stimulant found in high concentrations on certain cancer cells. By binding to HER2, pertuzumab inhibits or halts cancerous cell proliferation, potentially leading to cell death. The second agent, trastuzumab, also binds HER2, suppressing cancer cell growth and inducing apoptosis.
SAFETY ADVICE
AlcoholCONSULT YOUR DOCTOR
Alcohol consumption alongside Phesgo 600mg/600mg injectable solution hasn't been established as safe. Seek medical advice before combining them.
PregnancyCONSULT YOUR DOCTOR
Administering Phesgo 600mg/600mg Injection during pregnancy poses a confirmed risk to the fetus. Therefore, its use is contraindicated. In exceptional, life-threatening circumstances, a physician might prescribe it if the potential benefits outweigh the known dangers. Always seek medical advice.
Breast feedingCONSULT YOUR DOCTOR
The administration of Phesgo 600mg/600mg Injection Solution while breastfeeding is likely inadvisable. Available human data indicate potential transfer to breast milk, posing a possible risk to the infant.
DrivingUNSAFE
The injectable medication Phesgo (600mg/600mg) can induce adverse reactions that might impair driving ability. These may include dizziness, chills, fever, or injection site or allergic responses. Refrain from operating vehicles or machinery until these effects subside.
KidneySAFE IF PRESCRIBED
Phesgo 600mg/600mg injectable solution requires no dosage modification for patients with renal impairment and is considered safe for this population.
LiverCONSULT YOUR DOCTOR
Insufficient data exists regarding the administration of Phesgo 600mg/600mg injectable solution to individuals with hepatic impairment. Physician consultation is advised.
What if you forget to take Phesgo 600mg/600mg Solution for Injection :
Omit a Phesgo 600mg/600mg injectable dose? Seek your physician's advice.
Facts to Know About Phesgo 600mg/600mg Solution for Injection
| Label | Value |
|---|---|
| Developing Habits | No. |
| Treatment Category | Cancer Medications |
3,018 People bought this recently